Twitter Beğeni Hilesi

Dr. Neil Kay Mayo Clinic discusses MRD in CLL, highlighting a few pearls to consider 🩸 Blood can be used, with high concordance to BM (less so in CD20 regimens) 🧮 10^-4 sufficient 🩺 uMRD at EOT can guide PFS discussions, may not help guide treatment decisions at this time

Phenomenal work from Mark Roschewski diving into the biology and treatment strategies of immune privileged LBCL ashpublications.org/blood/article-… Looking forward to updated data from trials considering response adapted chemo after ibrutinib a window study for acalabrutinib

Energizing talk from Dr. Jeremy Abramson breaking down pros and cons of Pola-R-CHP The essential points of this talk apply to any new cancer therapy providing benefit over SOC (e.g. improved PFS, lower toxicity, etc) WITHOUT improved OS Quality of OS counts!!

Dr. David Miklos Stanford BMT & Cell Therapy kicks of Saturday at #DAVAHeme with intriguing update on secondary malignancy post-CD19 CAR nejm.org/doi/full/10.10… In this patient, the secondary TCL cells were present prior to CAR infusion. Novel mechanism for secondary malignancy post-CAR?

Dr. Doris Hansen Moffitt Cancer Center discusses CAR-T moving to earlier LOT in MM, necessitating more refined patient selection tools MyCARe is the first model to predict outcome to CAR based on: 🦴EMD/PCL 🧬High-risk cytogenetics 🩸Ferritin 💊LEN response ncbi.nlm.nih.gov/pmc/articles/P…

With BCMA CAR/BsAbs moving to earlier lines, new post-BCMA strategies are essential Bhagirath Dholaria, MD shares early phase 1 data for P-BCMA-ALLO1, an off the shelf CAR with deep responses and high response rate after prior BCMA Expanded data coming at IMS Myeloma Society next month!

Another novel BCMA allo-CAR-T presented by Adriana Rossi with an immune cloaking technology to reduce rejection The phase 1 CaMMouflage trial is currently enrolling! clinicaltrials.gov/study/NCT05722…

Dr. Jennifer Lue @MSKCC shares rationale for targeting BCL6. BCL6 modulates DNA repair facilitating germinal center affinity maturation and is aberrantly expressed in some FL/DLBCL Two BCL6 degraders are currently in development: clinicaltrials.gov/study/NCT06090… clinicaltrials.gov/study/NCT06393…

Dr. Shannon Maude Children's Hospital shares data on CD19 CAR reinfusion for pediatric ALL patients with early B cell recovery Reinfusion resulted in 50% response rate with very low rates of CRS or neurotoxicity, may reduce relapse risk, but more data needed ashpublications.org/bloodadvances/…

Dr. Vinod Pullarkat City of Hope shares pros/cons of CART as consolidation for B-ALL. ✅Easier logistics vs ASCT ✅Less toxic with low disease burden ❌Long term outcome w/o ASCT unclear ❌Cost, access Early data for NCT05707273 encouraging. Looking forward to update at #ASH2024

Dr. Robert Hasserjian Mass General Cancer Center kicks off MDS session w/ tour de force MDS classification lecture ➖Genetically-defined MDS classification can inform therapy ➖Blasts strongly prognostic, but likely reflect stage rather than subtype Need 6th edition WHO classification‼️

Exciting early results for synergistic combination of IRAK4i and BTKi in PCNSL presented by Christopher D'Angelo in our uncommon lymphoma session Expansion cohort for TakeAim Lymphoma trial is currently enrolling! clinicaltrials.gov/study/NCT03328…

The prognosis for DHL and BL patients with R/R disease is abysmal. Ariela Noy builds case for 1L bispecifics + chemo Fantastic Data and ongoing trial for Epco + RCHOP: ncbi.nlm.nih.gov/pmc/articles/P… clinicaltrials.gov/study/NCT05578… MSK Oncology Updates proposed trial for Epco + REPOCH

Could myeloma ✨be✨ any more crowded? Joshua Richter, MD, FACP kicks off final day of #DAVAHeme w/ nice review of DREAMM-7/DREAMM-8 which may bring blenrep back for another round 🏡Easily administered in community ⬇️CRS, ICANS, Infxn 💉Q4W-Q12W dosing Where do we squeeze it in?

Fascinating work being done with James Blachly in the rapidly emerging field of hereditary hematologic malignancies 🦓 Check out these referral indications to determine if your patient and their family may benefit from a HALT referral The James

Dr. Aaron Goldberg Memorial Sloan Kettering Cancer Center discusses single-cell MRD which is more sensitive and more descriptive of the clonal architecture of residual AML science.org/doi/10.1126/sc… Clinical trial to control MRD-positive AML is planned! clinicaltrials.gov/study/NCT06284…

Great talk from Dr. Denis Slaymon UCLA Health sharing the preclinical data supporting a chemo-free combination of tucatinib, trastuzumab, and ribociclib in HER2+ breast cancer. 📣Phase Ib/II trial currently enrolling: clinicaltrials.gov/study/NCT05319… #DAVABreast

Great work at Siteman Cancer Center and Fred & Pamela Buffett Cancer Center presented by Jairam Krishnamurthy and Dr. Nusayba Bagegni demonstrating that incomplete TKa suppression at C1D15 may identify pts with CDK 4/6i resistant tumors Two trials with DiviTum ongoing: clinicaltrials.gov/study/NCT04968… clinicaltrials.gov/study/NCT05977…

ADC resistance and sequencing is something of a black box, but Dr. Ana Garrido-Castro Dana-Farber’s Breast Oncology Center shares upcoming trial TRADE-DXd which aims to shed light on key unanswered questions Is there a preferred initial ADC? Who can benefit from sequencing? clinicaltrials.gov/study/NCT06533…

Exciting to see so many options emerging for germline BRCA1/2 mutation patients! 👏 judy garber shares multiple ongoing trials with targeted therapies and tumor vaccines that may one day expand options beyond prophylactic surgery or allow surgery to be deferred #DAVABreast